Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

    Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXCTWM2OD1yLkCwNFA2OTNizszN MonwV2FPT0WU
NCI-H1703 M1j3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfNZ4RqUUN3ME2wMlAxODlyMjFOwG0> MV\TRW5ITVJ?
KASUMI-1 NITIbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEC2PFIh|ryP MX;TRW5ITVJ?
CGTH-W-1 NHnKO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLzTWM2OD1yLkCwO|IzKM7:TR?= NXm3bYhwW0GQR1XS
A204 NGDEcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSyTWM2OD1yLkCwPVkzKM7:TR?= M4j1NXNCVkeHUh?=
HOP-62 NVW4cmtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFeyTJJKSzVyPUCuNVA5OzZizszN MlnkV2FPT0WU
H-EMC-SS NUDETXNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2SwNmlEPTB;MD6xNVAxPSEQvF2= MUnTRW5ITVJ?
KU812 NVqzUHhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMU[1O|ch|ryP MmXGV2FPT0WU
EM-2 M2LicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn35TWM2OD1yLkG2PFE3KM7:TR?= M3vQW3NCVkeHUh?=
LAMA-84 NHzXWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXvTWM2OD1yLkG3OlY2KM7:TR?= NE\tepNUSU6JRWK=
JAR NHPFWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL0UVRKSzVyPUCuNlM6QDlizszN M1uxR3NCVkeHUh?=
G-361 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXCVXU{UUN3ME2wMlMzOzJ3IN88US=> NGfzZVZUSU6JRWK=
KG-1 M{\SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf6fYlKSzVyPUCuN|c3PDJizszN MU\TRW5ITVJ?
BV-173 NUfNTocxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwM{mzNkDPxE1? NFrjclBUSU6JRWK=
K5 M3zoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XjNmlEPTB;MD60NlEzPyEQvF2= MX\TRW5ITVJ?
MEG-01 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD2TWM2OD1yLkSyN|YyKM7:TR?= M1n4b3NCVkeHUh?=
MFM-223 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rsTmlEPTB;MD60OFc4PiEQvF2= NVPSTpJ3W0GQR1XS
BE-13 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvNOVgyUUN3ME2wMlUyODB6IN88US=> MV\TRW5ITVJ?
NEC8 NIfSeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fpXmlEPTB;MD63NlEyOyEQvF2= NGC0PVZUSU6JRWK=
SW756 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF35WGtKSzVyPUCuPVk5PDZizszN MoCwV2FPT0WU
A2780 M{Pz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnjTWM2OD1zLkCxNVQ3KM7:TR?= M1zpUXNCVkeHUh?=
NB14 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnlTWM2OD1zLkCxPFAyKM7:TR?= M1nHU3NCVkeHUh?=
H4 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C3VmlEPTB;MT6wOlQzOiEQvF2= MknYV2FPT0WU
SK-OV-3 M17WcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq5[mRGUUN3ME2xMlA3PjN|IN88US=> MUjTRW5ITVJ?
AN3-CA NF\SbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF32NoRKSzVyPUGuNFg{QDlizszN M1XjT3NCVkeHUh?=
A427 NV21[3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHETWM2OD1zLkGwN|gyKM7:TR?= MX7TRW5ITVJ?
ES7 M3LhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELkPZRKSzVyPUGuNVE{OzRizszN NYHlOZZkW0GQR1XS
AGS MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwMUGzPVUh|ryP MULTRW5ITVJ?
G-402 NHzqbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwMUS2PVQh|ryP NUn6d49LW0GQR1XS
ES5 M2rVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnUclRlUUN3ME2xMlE4OjR6IN88US=> M3i1XHNCVkeHUh?=
DEL NGnNcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;ZbXBuUUN3ME2xMlI2PDV5IN88US=> MUHTRW5ITVJ?
NB10 NYnPfWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV62fIhpUUN3ME2xMlMzPTV5IN88US=> M{HHenNCVkeHUh?=
NCI-H1581 NXfwVGQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDqc3RKSzVyPUGuN|kxPDJizszN M3fDbHNCVkeHUh?=
D-566MG NGrLdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[wVGlEPTB;MT60NFY5OyEQvF2= MmDqV2FPT0WU
LXF-289 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfPTWM2OD1zLkSzPVk3KM7:TR?= MkTGV2FPT0WU
BT-549 M1HRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ySGNKSzVyPUGuOVY6ODlizszN Mni2V2FPT0WU
NKM-1 M2jLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwNkC1OVYh|ryP MWjTRW5ITVJ?
SW780 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwNkWxOVgh|ryP M{XnVHNCVkeHUh?=
NCI-H292 NFXa[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLDfnc1UUN3ME2xMlY3Ozh|IN88US=> NXP0TFFiW0GQR1XS
HMV-II NVvaUJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG5enhKSzVyPUGuO|A1QDhizszN M3vBNnNCVkeHUh?=
ALL-PO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHXdlJ2UUN3ME2xMlgxODF3IN88US=> MkfJV2FPT0WU
UACC-257 NVGwUlhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID6R25KSzVyPUGuPFIyPjNizszN MlHaV2FPT0WU
PA-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwOEK3NlUh|ryP NXjmU4NnW0GQR1XS
HD-MY-Z NXXofJR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfKU|E2UUN3ME2xMlg3OjhzIN88US=> MYPTRW5ITVJ?
HSC-4 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL0TYZGUUN3ME2xMlk{QDN7IN88US=> MWLTRW5ITVJ?
GCT NGTBcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvxTlFKSzVyPUKuNFA6OTZizszN NXTyNoh1W0GQR1XS
RT-112 M{DYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rzOGlEPTB;Mj6xN|QzPCEQvF2= M2jicHNCVkeHUh?=
A172 M2\rWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsbIZkUUN3ME2yMlE{PjB4IN88US=> NYLUR3A3W0GQR1XS
HCE-T NVXSW2xyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwMkC1PVgh|ryP NGnFSmhUSU6JRWK=
YH-13 NVflW2p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPp[3VmUUN3ME2yMlIyPjdzIN88US=> NHnJZpJUSU6JRWK=
DK-MG NU\xe5FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO1PIlKSzVyPUKuNlM5OzRizszN NWnIe5doW0GQR1XS
ACN MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHNTWM2OD1{LkKzPFc2KM7:TR?= NVrFdnlYW0GQR1XS
VA-ES-BJ NFTSfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[1S2pUUUN3ME2yMlI1QTV5IN88US=> MnTuV2FPT0WU
L-363 NXHtXos4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;6TWM2OD1{LkK4NFYyKM7:TR?= Mlu5V2FPT0WU
HuH-7 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfhTWM2OD1{LkSyNVY2KM7:TR?= MUfTRW5ITVJ?
A4-Fuk Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XTNWlEPTB;Mj60O|E3QCEQvF2= M2H5SnNCVkeHUh?=
T-24 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\PWHF3UUN3ME2yMlQ5ODN5IN88US=> MnXIV2FPT0WU
GOTO MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjCTWM2OD1{LkWzNFE{KM7:TR?= MX3TRW5ITVJ?
MV-4-11 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrSS5JQUUN3ME2yMlU6OTZ7IN88US=> MXnTRW5ITVJ?
DMS-114 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fGdmlEPTB;Mj62OlM1PSEQvF2= MmLjV2FPT0WU
MHH-NB-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rTTWlEPTB;Mj63NFI6QSEQvF2= MU\TRW5ITVJ?
CHP-212 NYfYOoxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3fmlEPTB;Mj64NlA6OSEQvF2= NV33co5XW0GQR1XS
DMS-273 NYfvRnFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV32XG1uUUN3ME2yMlkxOjB5IN88US=> MWDTRW5ITVJ?
SF295 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPnbGxFUUN3ME2zMlAzPTl5IN88US=> NX:z[JN[W0GQR1XS
NCI-H1563 NIDkOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjDTWM2OD1|LkG1NFA2KM7:TR?= MVnTRW5ITVJ?
NCI-H446 NYfhcopUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHsTWM2OD1|LkKyPFA2KM7:TR?= NHi2OYNUSU6JRWK=
HCC1806 NXq3TWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjuOZVQUUN3ME2zMlI4PjV5IN88US=> NWnncW5sW0GQR1XS
SF126 NV\4N|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PyN2lEPTB;Mz6zNFAyPyEQvF2= NF;mUYZUSU6JRWK=
SW982 NEPs[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTNwM{O4O|Uh|ryP NH\LN5NUSU6JRWK=
ES8 NX;JVpBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3CTWM2OD1|LkO0PVk6KM7:TR?= NUTrU|ZwW0GQR1XS
SCC-4 NGm5NZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rHVmlEPTB;Mz61NFM6PiEQvF2= NGTj[JNUSU6JRWK=
RPMI-8226 NIHMRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3nNZNKSzVyPUOuOlI3OTZizszN NVraTGREW0GQR1XS
EW-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GyXWlEPTB;Mz62N|AzOiEQvF2= MkDVV2FPT0WU
COR-L105 NV3uS3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS4T4NKSzVyPUOuOlM{OzRizszN MkToV2FPT0WU
ES1 NWT3eVl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTNwOEOwPVQh|ryP NX7uendsW0GQR1XS
KMOE-2 NH3nPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O1NGlEPTB;Mz65NVgxQCEQvF2= MkKyV2FPT0WU
ABC-1 M4\WNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;ITWM2OD1|LkmzPVEyKM7:TR?= NUCz[YQ3W0GQR1XS
NCI-H526 NFnSd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNwOUmxNlYh|ryP MXXTRW5ITVJ?
HCC1395 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjTUJVmUUN3ME2zMlk6PDh2IN88US=> MWXTRW5ITVJ?
DU-145 M4PyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrZTWM2OD12LkGyPFI2KM7:TR?= MXvTRW5ITVJ?
JEG-3 NFfKO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknRTWM2OD12LkG1PVE3KM7:TR?= NELiSIdUSU6JRWK=
HCC1187 M3GyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHrTWM2OD12LkKxOVk4KM7:TR?= MVjTRW5ITVJ?
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5fFlnUUN3ME20MlIzOTd5IN88US=> M12xe3NCVkeHUh?=
ONS-76 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjiTWM2OD12LkK0NVkzKM7:TR?= NUnwXXZQW0GQR1XS
CAL-27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjLXIdKSzVyPUSuNlQ{PDRizszN NFPOcpBUSU6JRWK=
8-MG-BA M3;ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYTWM2OD12LkK2OlU5KM7:TR?= NUK5XY41W0GQR1XS
HGC-27 M3LIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPiNIFEUUN3ME20MlI6PjZizszN NX3TXoVUW0GQR1XS
Hs-578-T MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDvTWM2OD12LkOxOFY5KM7:TR?= M{PaV3NCVkeHUh?=
EW-1 NWW3NGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDUTWM2OD12LkWzNFE1KM7:TR?= NYOxSGxzW0GQR1XS
SW1573 NUfKUFJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfJTWM2OD12LkW1NVY{KM7:TR?= MlXiV2FPT0WU
SNU-423 M1Syb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD12Lk[wO|kh|ryP MWTTRW5ITVJ?
HOS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTRwNkm3O{DPxE1? NX;SbohOW0GQR1XS
LB1047-RCC M4LrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLUR4h{UUN3ME20MlgyPDF6IN88US=> MnS2V2FPT0WU
ChaGo-K-1 M3zhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnYTWM2OD12Lki5NFQ5KM7:TR?= NH7tPJVUSU6JRWK=
A3-KAW MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXTTnVKSzVyPUSuPVc{PTJizszN NULRfI5wW0GQR1XS
CAS-1 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwOUm5NFgh|ryP Ml;MV2FPT0WU
NBsusSR MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfhT493UUN3ME21MlA{PTF2IN88US=> MYfTRW5ITVJ?
KM12 M3zBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTVwMkm4Nlch|ryP NVL1[WdzW0GQR1XS
NCI-H1155 M2jhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwM{ixPFUh|ryP Mn2zV2FPT0WU
EFM-19 NUOzeoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO1WXJPUUN3ME21MlQyPzN5IN88US=> NFHOOmVUSU6JRWK=
D-392MG M2DYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLGTWM2OD13LkW3PFQ6KM7:TR?= MXvTRW5ITVJ?
JVM-3 NYPo[I9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTVwN{KzNlUh|ryP NXPH[HI6W0GQR1XS
EW-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELKPFdKSzVyPUWuO|U2QDNizszN Mm\BV2FPT0WU
KARPAS-45 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLrSFBKSzVyPUWuPFQ{OjVizszN NGKwR5lUSU6JRWK=
NCI-H28 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nZemlEPTB;NT64O|kyQCEQvF2= Mnm3V2FPT0WU
COLO-829 NY\lepNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\weolzUUN3ME21MlkyPTB2IN88US=> MWTTRW5ITVJ?
KM-H2 M1;lNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[5NItWUUN3ME21MlkzOzl3IN88US=> NYflZlZlW0GQR1XS
NCI-H82 NYnyVI5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT3TWM2OD13LkmyO|cyKM7:TR?= MkfzV2FPT0WU
OAW-42 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr6TWM2OD13Lkm4PFIyKM7:TR?= MVvTRW5ITVJ?
A704 NH7UR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwMUC1O|Qh|ryP MnzvV2FPT0WU
NCI-H1048 NIK2WldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTZwMUC1PVkh|ryP M1zSWXNCVkeHUh?=
LOXIMVI NX7ZcpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LyXGlEPTB;Nj6xNVI1QCEQvF2= Mn[3V2FPT0WU
MKN45 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTZwMk[wNVYh|ryP MXTTRW5ITVJ?
D-502MG NXzYUVl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTZwMki4OVch|ryP M1\NXXNCVkeHUh?=
HUTU-80 M2P2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZwNEG2PFgh|ryP MmDCV2FPT0WU
S-117 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH5bGhKSzVyPU[uOVAzPjdizszN NVL2eYNyW0GQR1XS
HCC1569 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTaZmM1UUN3ME22MlU{PzN5IN88US=> MlvVV2FPT0WU
J-RT3-T3-5 NVP1PGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GyR2lEPTB;Nj61OFU4OiEQvF2= M{P0TnNCVkeHUh?=
OC-314 NIC0fppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\DfmlEPTB;Nj65NVE2QSEQvF2= M4HQR3NCVkeHUh?=
SNU-449 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLsTWM2OD15LkCxNFczKM7:TR?= M{DLSnNCVkeHUh?=
NCI-H720 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTdwMUmzOFUh|ryP MX7TRW5ITVJ?
KP-N-YS MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTyUmhKSzVyPUeuNlA4OiEQvF2= M1nFV3NCVkeHUh?=
IGROV-1 M120XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTdwM{KzPFYh|ryP NXvpS2RjW0GQR1XS
SK-PN-DW MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTNTWM2OD15LkS4NVUh|ryP NEnPN2lUSU6JRWK=
HCC1419 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3tZYRKSzVyPUeuOVMh|ryP MoXKV2FPT0WU
HAL-01 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGyOnFkUUN3ME23MlYxPjR2IN88US=> MYfTRW5ITVJ?
HCC2998 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK5dpNKSzVyPUeuOlA4PDNizszN M2T0XHNCVkeHUh?=
SK-N-FI MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvTTWM2OD15Lk[zNFM{KM7:TR?= NFPSOlZUSU6JRWK=
GI-ME-N MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLy[WFKSzVyPUeuOlQ6OzRizszN NVTvUmVEW0GQR1XS
SW1088 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nxfmlEPTB;Nz62OVgzPiEQvF2= M{\LT3NCVkeHUh?=
IA-LM MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTrOZF4UUN3ME23MlY5PjF|IN88US=> Mmq0V2FPT0WU
SK-NEP-1 NWmxemFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TXUGlEPTB;Nz62PVYyKM7:TR?= M2fjcnNCVkeHUh?=
MDA-MB-415 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfnPYk1UUN3ME23Mlg6OTh4IN88US=> NYD1bZZEW0GQR1XS
COLO-800 NGn3clhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;YTWM2OD15Lkm0OFkzKM7:TR?= NUjEWoRtW0GQR1XS
NCI-H2228 NXntcJg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\1dZZqUUN3ME24MlE2Pzh|IN88US=> MlywV2FPT0WU
D-423MG MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5[oNKSzVyPUiuNlE4OiEQvF2= MkLXV2FPT0WU
TE-1 NXnSWph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXxV49KSzVyPUiuOFQ{OTZizszN MWrTRW5ITVJ?
NOS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqwOm13UUN3ME24MlUyPTN2IN88US=> NWPLbZRyW0GQR1XS
8505C MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRThwNkS4NlQh|ryP MWXTRW5ITVJ?
HEC-1 NXPVcmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvoUXN5UUN3ME24Mlc5PDN7IN88US=> M4TiUXNCVkeHUh?=
TE-11 NWL0SXB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;kTWM2OD16Lkm5OVUyKM7:TR?= MofmV2FPT0WU
CTB-1 NWrJR3Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTITWM2OD17LkCxOFM{KM7:TR?= MX7TRW5ITVJ?
TGBC11TKB NGr6boVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL2dZV2UUN3ME25MlAzOjRzIN88US=> NXXYb2t7W0GQR1XS
NB17 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj1OoZKSzVyPUmuNVg5PyEQvF2= MXHTRW5ITVJ?
Becker NHHlWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmwNXBKSzVyPUmuOFE6PDRizszN MUnTRW5ITVJ?
SN12C M2fqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTlwNEWyN|Qh|ryP M2q3dnNCVkeHUh?=
COLO-320-HSR NVPBdWFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLOTWM2OD17Lk[wNlM4KM7:TR?= Ml3nV2FPT0WU
D-283MED MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HtemlEPTB;OT62N|A4OiEQvF2= M1TPeHNCVkeHUh?=
D-263MG NUjw[ZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrmfVBKSzVyPUmuPFM{QDRizszN NGj2W4VUSU6JRWK=
MEL-JUSO MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGxTWM2OD17LkmwNVI4KM7:TR?= MYTTRW5ITVJ?
T98G NYXGRZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm5TWM2OD17LkmwNlA{KM7:TR?= Mof1V2FPT0WU
HLE NYf4RpQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHYcpdKSzVyPUmuPVA6ODlizszN NIW0e2FUSU6JRWK=
Ca9-22 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPYTWM2OD1zMD6wOlY2KM7:TR?= MnjYV2FPT0WU
OS-RC-2 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Kyb2lEPTB;MUCuNVA1PSEQvF2= MU\TRW5ITVJ?
T47D MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yzbWlEPTB;MUCuNVU2KM7:TR?= MkjHV2FPT0WU
GI-1 NX\DZ4ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3mVY9KSzVyPUGwMlM2OzNizszN MoTIV2FPT0WU
NUGC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISzU2xKSzVyPUGwMlQ1ODJizszN MYDTRW5ITVJ?
MDA-MB-361 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT4T45KSzVyPUGwMlQ1OzJizszN M1zm[HNCVkeHUh?=
SCC-15 NHzXT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFyLkS3NVgh|ryP MVHTRW5ITVJ?
KS-1 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXKOWZKSzVyPUGwMlY{ODFizszN NXvMNHJ2W0GQR1XS
CAL-12T Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzBXol6UUN3ME2xNE43OzZzIN88US=> M3rFNXNCVkeHUh?=
OVCAR-4 M2jhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHftT21KSzVyPUGwMlcxPjhizszN MknzV2FPT0WU
HuP-T4 NH7STVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HWT2lEPTB;MUGuNFMzQCEQvF2= NI\vd21USU6JRWK=
NCI-H358 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFzLkK2OVch|ryP NV\6UnJoW0GQR1XS
HO-1-N-1 M3rQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCxbY1{UUN3ME2xNU4{Ozl6IN88US=> NG[4PYRUSU6JRWK=
NH-12 M1nKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzBTWM2OD1zMT61N|c5KM7:TR?= NWDveFhIW0GQR1XS
MOLT-4 NWTIcZdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Rb5IzUUN3ME2xNU42QTh3IN88US=> NIf2Z2xUSU6JRWK=
K-562 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HkeWlEPTB;MUGuO|I1QCEQvF2= MlHUV2FPT0WU
ES6 NWKwfpFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u4d2lEPTB;MUGuPFU5OSEQvF2= MXfTRW5ITVJ?
RO82-W-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrJPW1KSzVyPUGxMlkxPjRizszN M{HKenNCVkeHUh?=
Ramos-2G6-4C10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPQTWM2OD1zMT65N|Ih|ryP MXvTRW5ITVJ?
23132-87 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33rfmlEPTB;MUKuNFgzOSEQvF2= NUXvWlRtW0GQR1XS
A549 MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W0[WlEPTB;MUKuN|I5PSEQvF2= Mn;0V2FPT0WU
NCI-H23 M1vvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jHOmlEPTB;MUKuOVAzPiEQvF2= NY[y[olWW0GQR1XS
H9 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjBTWM2OD1zMj61OVc4KM7:TR?= NIj0cllUSU6JRWK=
LB771-HNC MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\XTWM2OD1zMj63OlUh|ryP MU\TRW5ITVJ?
QIMR-WIL NETQeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF{LkiyOVgh|ryP M1jZSHNCVkeHUh?=
HSC-3 NXnKfZZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWxRZZvUUN3ME2xNk46Ojd4IN88US=> NXHkc3hzW0GQR1XS
PFSK-1 NXvrXIlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi3WpRRUUN3ME2xNk46PTB5IN88US=> M{HCbXNCVkeHUh?=
ETK-1 NIjuWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF|LkC3O|kh|ryP M4rQcHNCVkeHUh?=
SW1710 NF2zcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLaTWM2OD1zMz6zOlQyKM7:TR?= NV3tZ5BEW0GQR1XS
COLO-684 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nPTmlEPTB;MUOuOFU1OSEQvF2= MYLTRW5ITVJ?
RPMI-7951 NWf2VYloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\jZmlEPTB;MUOuOVE{PiEQvF2= M4DEbnNCVkeHUh?=
A101D NXLvdZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIiwcFNKSzVyPUGzMlU{PDlizszN NVjHRXM4W0GQR1XS
KE-37 NG\GVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrpdo1KSzVyPUGzMlU5QDdizszN NFL1NXRUSU6JRWK=
SiHa NV\jTmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC3Z3Z{UUN3ME2xN{45OzR4IN88US=> Mnj2V2FPT0WU
NCI-H226 NV3TWpptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr2VFJwUUN3ME2xN{45QDB6IN88US=> MmfjV2FPT0WU
DB M3H1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILXR5ZKSzVyPUGzMlk6OjhizszN MkniV2FPT0WU
HT-1197 NX3XTnBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHznOohKSzVyPUG0MlA5ODlizszN NIe3b25USU6JRWK=
SBC-5 M2SyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrHTWM2OD1zND6xN|YzKM7:TR?= MlOxV2FPT0WU
VMRC-RCZ M{frZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LVRWlEPTB;MUSuOVc4PCEQvF2= NU\wOFdOW0GQR1XS
697 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfEWVEzUUN3ME2xOE43OjdizszN MojDV2FPT0WU
OMC-1 NFqwfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK0TWM2OD1zND63PFg5KM7:TR?= MY\TRW5ITVJ?
SKG-IIIa NInu[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXnTVN4UUN3ME2xOE45ODBzIN88US=> MWHTRW5ITVJ?
DOK MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLweJlKUUN3ME2xOE46QTN|IN88US=> M3zpcnNCVkeHUh?=
NCI-H2029 NGfMc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvaTWM2OD1zNT6zOlAzKM7:TR?= M2PsNnNCVkeHUh?=
NCI-H2009 NXPPN2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TLVGlEPTB;MUWuOVA6PSEQvF2= MoLRV2FPT0WU
LK-2 M1r3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu0TWM2OD1zNT62OFQ6KM7:TR?= MofUV2FPT0WU
NCI-H661 M{DuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITmToxKSzVyPUG1MlkxPzVizszN MYHTRW5ITVJ?
GT3TKB NF3rTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LKXmlEPTB;MU[uNFY4PiEQvF2= MnTxV2FPT0WU
GP5d MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\MdYtKSzVyPUG2MlM1OiEQvF2= Mk\JV2FPT0WU
SK-MEL-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonnTWM2OD1zNj60OFg2KM7:TR?= Mn:2V2FPT0WU
SK-UT-1 NFLhNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\aTWM2OD1zNj61OlUh|ryP MV;TRW5ITVJ?
NB7 NUHkWWJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT6fnJ7UUN3ME2xOk43QTdzIN88US=> NWOyfIg6W0GQR1XS
NCI-H460 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;UWXlwUUN3ME2xOk44OzJ4IN88US=> NYLPNm9bW0GQR1XS
8305C MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXHTWM2OD1zNj63PFc4KM7:TR?= NHfMUHJUSU6JRWK=
CaR-1 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLuTWM2OD1zNj64NVEyKM7:TR?= NEH6fFJUSU6JRWK=
D-247MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvwTWM2OD1zNj64OlI2KM7:TR?= MonOV2FPT0WU
LoVo MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPYTWM2OD1zNj65OFg5KM7:TR?= Mn;HV2FPT0WU
NCI-H2405 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW0dVdKSzVyPUG3MlE6ODhizszN NWH2U45QW0GQR1XS
AU565 NIDRSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWzN3pyUUN3ME2xO{4zOjVizszN Mnn5V2FPT0WU
OCI-AML2 M3HiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF5LkWzNVch|ryP M1HUV3NCVkeHUh?=
22RV1 NXS3WZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF5LkW4PFQh|ryP MUHTRW5ITVJ?
HT-144 M{HObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTuTWM2OD1zNz62OVk5KM7:TR?= MVvTRW5ITVJ?
HuO9 NF3WR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV21SmZIUUN3ME2xO{44ODNzIN88US=> M2nhOHNCVkeHUh?=
Daoy NVGzRZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnOTFRPUUN3ME2xO{44OTh2IN88US=> MnXTV2FPT0WU
SJRH30 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUeyO2txUUN3ME2xO{45PDh7IN88US=> M1vDXHNCVkeHUh?=
CHL-1 NFfS[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF5LkmyOFkh|ryP NGm3XZJUSU6JRWK=
J82 NV20SZZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\JNWlKSzVyPUG3Mlk3OzVizszN NFHaOndUSU6JRWK=
COR-L23 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr2TWM2OD1zOD6wNFEyKM7:TR?= M{nNb3NCVkeHUh?=
SNU-C2B NH\SeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTLTWM2OD1zOD6yNlc3KM7:TR?= MXXTRW5ITVJ?
NCI-H1770 M4\MbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF6LkS2NVUh|ryP MorLV2FPT0WU
MHH-PREB-1 NX;PdHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHBRllKSzVyPUG4MlU3QTdizszN M2j6[XNCVkeHUh?=
ES3 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mxd2lEPTB;MUiuOVg5OyEQvF2= MojsV2FPT0WU
MDA-MB-231 NVWycINvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF6Lk[1NFIh|ryP MYDTRW5ITVJ?
MN-60 NVGxcWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq5bGV[UUN3ME2xPU4xPTl{IN88US=> NIfSV4NUSU6JRWK=
EPLC-272H MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf5dlFRUUN3ME2xPU4{PzB6IN88US=> M1GyS3NCVkeHUh?=
SW948 NUnoRo5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF7LkO5N|Qh|ryP MoHpV2FPT0WU
MOLT-13 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L0VWlEPTB;MUmuOFU1PiEQvF2= NVWyVHg2W0GQR1XS
HL-60 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjUbWFCUUN3ME2yNE4zOTRzIN88US=> NE\DeHpUSU6JRWK=
CP50-MEL-B M{jjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrpTWM2OD1{MD60O|Q5KM7:TR?= NX;XSmFIW0GQR1XS
NTERA-S-cl-D1 NITSV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJyLkS5O|gh|ryP MlzKV2FPT0WU
KINGS-1 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nLfmlEPTB;MkCuO|k3PyEQvF2= MVnTRW5ITVJ?
DOHH-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJyLkmwOkDPxE1? MmHqV2FPT0WU
BB65-RCC MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2VHBKSzVyPUKwMlkzQDVizszN MX7TRW5ITVJ?
NB12 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXJTWM2OD1{MT6wN|k1KM7:TR?= MoS4V2FPT0WU
KY821 NH\YW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDRTWM2OD1{MT61PFIh|ryP MYrTRW5ITVJ?
PSN1 NYLHeYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJzLk[0OVMh|ryP MVTTRW5ITVJ?
EGI-1 NGPUeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJzLke0OVQh|ryP M3zRdnNCVkeHUh?=
CTV-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HhZmlEPTB;MkKuN|A{OSEQvF2= NEOxWIFUSU6JRWK=
TI-73 NYroUlg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ{LkO0PVgh|ryP M3f5enNCVkeHUh?=
LCLC-103H NGrZeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjPbYxKSzVyPUKyMlQ4PTJizszN Ml3GV2FPT0WU
D-542MG NIK0TJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzGT49KSzVyPUKyMlU2PThizszN MmjKV2FPT0WU
ATN-1 NFrxelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImwUmJKSzVyPUKyMlY1OzlizszN NFvte25USU6JRWK=
SK-MEL-1 NIfid|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[4d4E1UUN3ME2yNk45OzZ6IN88US=> MofaV2FPT0WU
HDLM-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TkemlEPTB;MkOuNVQ4QCEQvF2= MoX6V2FPT0WU
UM-UC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ|LkG5OFQh|ryP NIPUPYlUSU6JRWK=
NCI-H1573 NEPVZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmflTWM2OD1{Mz60OlgyKM7:TR?= NI[yfmhUSU6JRWK=
NCI-H520 NYG0W3FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[zdHBKSzVyPUKzMlQ6PDhizszN M2PVXnNCVkeHUh?=
ESS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H2O2lEPTB;MkOuPFA2QSEQvF2= MXTTRW5ITVJ?
COR-L88 NF;oT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ|Lkm0O|Uh|ryP M2LPNHNCVkeHUh?=
TGBC24TKB NWXtcI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPLdFIxUUN3ME2yOE4xOzF{IN88US=> NH3PdnVUSU6JRWK=
HCC1937 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfXVmRxUUN3ME2yOE4yKM7:TR?= NW\SSWNJW0GQR1XS
RS4-11 NVHLRYxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ2LkG0NkDPxE1? Mo[0V2FPT0WU
HCC38 NETwdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rWVmlEPTB;MkSuNlM6PCEQvF2= NGjYWFJUSU6JRWK=
RPMI-2650 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13kPGlEPTB;MkSuOlE3OiEQvF2= NF7ObFVUSU6JRWK=
P12-ICHIKAWA M3Pn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\zXoZKSzVyPUK0MlYzPThizszN M{nrUnNCVkeHUh?=
YAPC M4PteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ2LkiyNVQh|ryP NGW1b|NUSU6JRWK=
NB13 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HyeGlEPTB;MkWuNlYyOSEQvF2= MYDTRW5ITVJ?
SK-N-AS NUTuRWxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\qc3U{UUN3ME2yOU45PTh2IN88US=> MnS0V2FPT0WU
SK-N-DZ NWryWmd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDVZpKSzVyPUK2MlA1QSEQvF2= MlOwV2FPT0WU
LS-411N MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInCU4ZKSzVyPUK2MlIxOzhizszN NWPaWI1rW0GQR1XS
NCI-H810 M2CxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX0d4ZtUUN3ME2yOk4{OTF{IN88US=> NVG0eYx2W0GQR1XS
NCI-SNU-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PRNWlEPTB;Mk[uOVQ2PCEQvF2= NXvBd29HW0GQR1XS
HH NVj0OW5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fvbWlEPTB;Mk[uOVUzQSEQvF2= MXPTRW5ITVJ?
U-2-OS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXtTWM2OD1{Nj63N|gzKM7:TR?= M2fIbXNCVkeHUh?=
SF539 M1TuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[zW4NKSzVyPUK2MlgxOThizszN MYXTRW5ITVJ?
NCI-H2052 M{fW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jz[GlEPTB;MkeuNFg3KM7:TR?= MkHsV2FPT0WU
A673 NHzDW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ5LkKxNFIh|ryP MXrTRW5ITVJ?
WM-115 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HvemlEPTB;MkeuO|c3PyEQvF2= NF[xTnJUSU6JRWK=
SW48 NETafXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof6TWM2OD1{Nz64NFA2KM7:TR?= Mk\oV2FPT0WU
NOMO-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37sXmlEPTB;MkeuPFU{OiEQvF2= MluwV2FPT0WU
PC-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHWVFlKSzVyPUK3Mlg6PDFizszN NWW0dWRDW0GQR1XS
UMC-11 NXjnTodmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHBSFFLUUN3ME2yO{46OzR|IN88US=> MoDuV2FPT0WU
U-118-MG NWfuSWNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGflV5BKSzVyPUK4MlAyOjNizszN MVPTRW5ITVJ?
NCI-H2452 M1LZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\FXWhKSzVyPUK4MlA5OjJizszN NIHI[JRUSU6JRWK=
CAMA-1 Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfxdVNvUUN3ME2yPE45PTZ2IN88US=> NF3rdWxUSU6JRWK=
MC-IXC M2jlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXDTJB2UUN3ME2yPU4zOzZ4IN88US=> MY\TRW5ITVJ?
ES4 M{LFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzTW25KSzVyPUK5MlMyPzJizszN NWHpZnhtW0GQR1XS
BHT-101 M{HqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\mUGZWUUN3ME2yPU4{OjFizszN NHHCUWFUSU6JRWK=
KP-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3MOmFPUUN3ME2yPU42OTZizszN MX3TRW5ITVJ?
CAL-54 NH7rPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M173V2lEPTB;MkmuOVQ1PSEQvF2= Mn7BV2FPT0WU
5637 NWn5PFhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULHRYp3UUN3ME2yPU43PDJzIN88US=> MmPUV2FPT0WU
MOLT-16 M2DtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ7LkeyOlkh|ryP M3zje3NCVkeHUh?=
Ca-Ski NFrJeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJ7Lkm0OkDPxE1? NX33XotzW0GQR1XS
AsPC-1 M{PrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNyLkCyNVIh|ryP MVXTRW5ITVJ?
MSTO-211H NIjF[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13J[2lEPTB;M{CuNVUh|ryP NY\ocIZYW0GQR1XS
L-428 NHLoU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\QT45KSzVyPUOwMlQxPSEQvF2= M3y1WnNCVkeHUh?=
SW1463 NH\FW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TtdGlEPTB;M{CuOVM5OyEQvF2= M37RVnNCVkeHUh?=
NCI-H1648 NGL1eoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNyLkW1O|Qh|ryP MXjTRW5ITVJ?
CAKI-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXNTWM2OD1|MD63O|AzKM7:TR?= M2q1T3NCVkeHUh?=
YKG-1 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDycnhKSzVyPUOxMlAzPjNizszN NYrJWVZ7W0GQR1XS
A2058 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNzLkGxOlQh|ryP M1HqSnNCVkeHUh?=
A375 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXtTWM2OD1|MT6xOlk3KM7:TR?= MVXTRW5ITVJ?
SNB75 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPTUJFKSzVyPUOxMlI1OzVizszN M3fzbnNCVkeHUh?=
SK-HEP-1 M3[0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNzLkSyO|Eh|ryP NHPB[JJUSU6JRWK=
ME-180 NIfCcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknyTWM2OD1|MT62OVQzKM7:TR?= NITnR4lUSU6JRWK=
NCI-H209 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNzLkiyOFch|ryP MlXzV2FPT0WU
HC-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfwUIlKSzVyPUOyMlE1PDZizszN NGexc3lUSU6JRWK=
LB373-MEL-D NXnuOIlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPuTWM2OD1|Mj6xPVcyKM7:TR?= Ml;TV2FPT0WU
SNU-387 NX[2cWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP3TWM2OD1|Mj6zNVkyKM7:TR?= NUHsdYN{W0GQR1XS
C32 NX;FeWQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTN{LkOzOVMh|ryP MmLuV2FPT0WU
EW-13 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfpTWM2OD1|Mj65OFA5KM7:TR?= MX3TRW5ITVJ?
BFTC-905 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTjS2NKSzVyPUOzMlUyOzZizszN NGjHN4dUSU6JRWK=
NCI-H1299 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33xcGlEPTB;M{OuOVYzOSEQvF2= NX;DW3p7W0GQR1XS
LU-135 NHjHbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm0Nng5UUN3ME2zN{45ODFizszN M1jlb3NCVkeHUh?=
NCI-H2122 M3HkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN|Lkm5OlYh|ryP MWDTRW5ITVJ?
SK-LMS-1 M3jrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTN2LkSxNFch|ryP NHThS3hUSU6JRWK=
LNCaP-Clone-FGC NUjSOlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTN2Lki1NVUh|ryP MYDTRW5ITVJ?
NCI-H1092 M1fYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHUTWM2OD1|NT6yO|Q4KM7:TR?= NEj0XXlUSU6JRWK=
MS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN3LkOwN|gh|ryP NVLFPXZCW0GQR1XS
KYSE-510 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX6XmhKSzVyPUO1MlUxPDJizszN M2LibnNCVkeHUh?=
NCI-H1793 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fiUWlEPTB;M{WuOlU1PSEQvF2= NVXjN3c5W0GQR1XS
MIA-PaCa-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;jTWM2OD1|Nj6wOFk3KM7:TR?= M2DJPXNCVkeHUh?=
EW-22 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDmXVhYUUN3ME2zOk41ODd{IN88US=> MkjiV2FPT0WU
IGR-1 M3HibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\aOlFKSzVyPUO2MlgyQDRizszN MWnTRW5ITVJ?
HT-1080 NWfFW2szT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vXS2lEPTB;M{euNVI2KM7:TR?= NWrQTFc1W0GQR1XS
M14 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\Ze4lUUUN3ME2zO{4yPjR{IN88US=> NYr5SJFKW0GQR1XS
786-0 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvXTWM2OD1|Nz6yO|k1KM7:TR?= NIHXVJRUSU6JRWK=
MZ2-MEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HVNmlEPTB;M{euOFUxOSEQvF2= NUOwPZRLW0GQR1XS
NCI-H510A NWnycllmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi3Z5l7UUN3ME2zO{46PDF{IN88US=> MWDTRW5ITVJ?
LAN-6 Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPVOo1KSzVyPUO3Mlk2QDJizszN MkTNV2FPT0WU
SW620 NV3VdHV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrpTWM2OD1|OD60PVc1KM7:TR?= NUjrXYdbW0GQR1XS
LB2241-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVexXXB6UUN3ME2zPU45OjB3IN88US=> M1Pn[3NCVkeHUh?=
Detroit562 NEHvN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TDPWlEPTB;NECuNVI3QCEQvF2= M3LhV3NCVkeHUh?=
HN NHTU[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml65TWM2OD12MD6xO|gzKM7:TR?= M4XRW3NCVkeHUh?=
HCT-15 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[yWmlEPTB;NECuOVkxPyEQvF2= M4XnfnNCVkeHUh?=
C2BBe1 NX\aNGpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vaVmlEPTB;NECuPVE2PyEQvF2= MmO1V2FPT0WU
A498 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzQ[I9DUUN3ME20NU4{ODF3IN88US=> MnG3V2FPT0WU
SK-MEL-24 M1GyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HaUWlEPTB;NEGuOFczPSEQvF2= MVzTRW5ITVJ?
OVCAR-5 NXvYbWd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn70TWM2OD12MT63O|Y4KM7:TR?= MUXTRW5ITVJ?
NCI-H1792 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\m[lRPUUN3ME20NU46QDJzIN88US=> M1H1PHNCVkeHUh?=
KOSC-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR{LkK2PVkh|ryP NWn6dnB6W0GQR1XS
Mo-T M3LTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfRe5VKSzVyPUSyMlg6PThizszN Mm\LV2FPT0WU
CFPAC-1 NWHpU5VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnvWmlKSzVyPUSzMlQ6PDRizszN NWTw[WlCW0GQR1XS
CAL-51 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXGTWM2OD12Mz61OlA2KM7:TR?= NITIOGlUSU6JRWK=
RH-18 NITsVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH70XW5KSzVyPUSzMlgxPSEQvF2= MkTqV2FPT0WU
EC-GI-10 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33UPGlEPTB;NEOuPFM1PyEQvF2= NGjPVnNUSU6JRWK=
HSC-2 NWHKN3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf5c3BKSzVyPUS0MlAxQSEQvF2= NH;xXmlUSU6JRWK=
ML-2 NHfxRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PlVWlEPTB;NEWuNlYzOSEQvF2= NGDoZXhUSU6JRWK=
KNS-81-FD NGDVdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvvbHRzUUN3ME20OU44OzZ3IN88US=> M1nDNnNCVkeHUh?=
NB6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTR4LkGxNUDPxE1? MULTRW5ITVJ?
MCF7 M1rodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XPRWlEPTB;NE[uOVU{OyEQvF2= NUm0[ZZPW0GQR1XS
P30-OHK NEPvfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[5TWM2OD12Nj64NVE4KM7:TR?= NI\2foZUSU6JRWK=
BPH-1 NY[yZYlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPDfFZKSzVyPUS2Mlk5ODVizszN NInCeJdUSU6JRWK=
U251 NUfISHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KyXWlEPTB;NE[uPVk1KM7:TR?= NHfYWY9USU6JRWK=
MKN1 NIrFcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PsR2lEPTB;NEeuOVE{PyEQvF2= Mn;GV2FPT0WU
A431 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Nc3BKSzVyPUS3Mlg{OzhizszN NFru[IVUSU6JRWK=
C8166 NEDmPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DJbWlEPTB;NEmuNlA{QSEQvF2= M1XmXHNCVkeHUh?=
HEL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7TTWM2OD12OT60NFY1KM7:TR?= MofxV2FPT0WU
RMG-I NEi3[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fVTWlEPTB;NEmuOFQ1PCEQvF2= Ml;MV2FPT0WU
CAL-72 M1[wNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:4cmlEPTB;NEmuOlA4PSEQvF2= Mn;SV2FPT0WU
SW962 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPuTWM2OD12OT65N|MzKM7:TR?= NFvDWnVUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
0.5% CMC
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID